INTRODUCTION
Pseudomyxoma peritonei (pmp) is a rare clinical condition defined as extensive intraperitoneal spread of mucus associated with variety of mucinous tumours of varying biologic behavior 1, 2 . The incidence of pmp is about 1-2 per million population 3, 4 . Low incidence forecloses the possibility of large-scale studies, and as a result there is broad diversity in the definitions, pathology, site-of-origin theories, treatment protocols, and prognosis for this disease 5 .
The clinical entity of pmp embraces a wide spectrum of neoplasms from the benign and borderline to malignant lesions with invasive growth capacity 3, 6 .
During the prolonged clinical course of the disease, massive gelatinous ascites causes compression of the intra-abdominal organs, mechanical and functional gastrointestinal obstructions, and dyspnea leading to cachexia and, potentially, death 2, 32, 38, 39, 41 . Pseudomyxoma peritonei often relapses, each time after a shorter interval, and local tumour recurrence can be expected in 60%-91% of the operated population (depending on the report), with a median disease-free interval of only 24 months, often leading to multiple operations 2, 23, 33, 41, 42 .
Repeated intervention is an important aspect of pmp management. Interventions are associated with an increasing rate of mortality (ranging from 0% to 18%), perioperative morbidity (major complications requiring re-operation or intensive care, or causing chronic disability, are reported in 27%-70% of cases), and long-term treatment complications, of which aggregating adhesive disease is central to the debilitated condition of patients 2, 39, [41] [42] [43] .
To summarize, although tumour growth usually tends to remain confined to the abdomen for many years, and blood-borne and lymph node metastases are uncommon, the disease has the potential for aggressive clinical behavior, including local tumour recurrence, and is always lethal unless radically treated 1, 5, 42, 43, 47, 48 .
CASE SUMMARY
A 50-year-old white man with no significant past medical history was admitted to the Second Department of General and Oncological Surgery of Wroclaw Medical University with a tumour of the lower abdomen. The patient reported a 4-month history of intermittent lower abdominal pain radiating to the back. He denied other ailments, recent weight changes, or abdominal distention.
On admission, the patient's general condition was good. His physical exam was notable only for a palpable tender mass in the central lower abdomen. Laboratory tests revealed mild monocytosis, with 11.4% white blood cells, and an elevated level of fibrinogen. Tumour marker studies were insignificant (carcinoembryonic antigen 0.5 ng/mL, and carbohydrate antigen 19-9 3.72 U/mL).All other blood and urine analyses, and chest radiography completed before surgery, showed no abnormalities.
Ultrasonography revealed a unilocular, solid, heterogenous, hypoechogenic, well-circumscribed tumour with fibrous partitions in the central lower abdomen, measuring 42×44×78 mm and extending from the anterosuperior dome of the urinary bladder to the anterior abdominal wall. Computed tomography imaging demonstrated the presence in the central lower abdomen of a heterogenous, hypodense, irregular polycystic mass with minute peripheral calcifications and without contrast enhancement, compressing and modelling intestine ( Figure 1) ; mesenteric cyst was a primary consideration in the differential diagnosis. Evaluation for distant metastases was negative.
The patient subsequently underwent laparotomy. Revision of the abdominal cavity disclosed a polycystic mass emanating from the urachal remnant and mucinous material confined to the rectovesical excavation ( Figure 2 ). The appendix was explored and considered to be normal-appearing. Evaluation for distant metastases and lymph node involvement was negative. The tumour was entirely removed within macroscopically healthy margins, including the extended aspect of parietal peritoneum and umbilical ligament. Partial cystectomy was performed. Approximately 150 mL of thick translucent yellow mucinous material was collected from the rectovesical excavation, and thorough lavage was performed. This procedure resulted in a macroscopically complete cytoreduction [Sugarbaker completeness of cytoreduction (cc) score 43 of 0].
The postoperative course was uneventful. At the time of article submission, our patient had been referred to long-term follow-up, but considering the low histologic aggressiveness (low-grade mucinous neoplasm, disseminated peritoneal adenomucinosis), the macroscopically complete cytoreduction, and the microscopically negative margins, no adjuvant chemotherapy was administered.
Pathology Findings
Macroscopic examination of the specimen revealed a well-circumscribed, gelatinous, polycystic mass emanating from the urachal remnant and measuring 8×7×4.5 cm, with abundant mucin within the lumen (Figure 3) . In cross-section, the tumour was composed of smooth-walled cysts containing mucin pools. The mass did not include any papillary or solid lesions and did not communicate with the urinary bladder lumen.
Histologically, the cysts were lined by a tall columnar epithelium, with slight cellular crowding and stratification. The epithelium showed features of simple benign columnar epithelium without areas of dysplasia. Cytologically, the lining columnar cells had abundant mucin in the cytoplasm and showed a slight degree of loss of polarity, but no pleomorphism or mitotic figures were present. No stromal invasion of the tumour cells was observed, although mucin was extravasated into the cyst wall. The association of this tumour with the urachal remnant and its location just anterior to the dome of the urinary bladder confirmed the primary urachal origin. The mucinous material collected from the rectovesical excavation was extensively histologically sampled, but no malignant cells were detected in the specimens.
Histopathologic interpretation was consistent with pmp potentially originating from the urachal remnant (World Health Organization classification: low-grade mucinous neoplasm, disseminated peritoneal adenomucinosis). The specimen margins were free of infiltration. No malignant penetration or presence of mucus within the urinary bladder wall was detected. Figure 4 presents selected images from the pathology evaluation.
DISCUSSION
The urachus is a tubular structure extending medially from the apex of the bladder to the allantoid during fetal development; normally obliterating after birth, it converts into the median umbilical ligament. Its lumen is lined with a transitional epithelium that has the potential for focal glandular metaplasia, possibly followed by malignant transformation. Vestigial persistence of this duct is revealed in 30%-70% of autopsies 33 . Urachal figure 2 Intraoperative picture of polycystic mass emanating from the apex of the urinary bladder. figure 3 Gross appearance of excised polycystic tumour containing abundant mucin. figure 
Histologic presentation of low-grade mucinous neoplasm. (A) Tumour shows a circumferential growth pattern and areas of mucin extrusion through the wall. (B) The epithelial lining consists of slightly stratified columnar cells containing mucin. (C) The underlying stroma shows extensive mucin extravasations without tumour cells. (D) The tumour cells contain abundant cytoplasmic mucin and enlarged hyperchromatic nuclei that are basally located, with minimal atypia. Hematoxylin-eosin stain, 40× (A and C) and 100× (B and D) original magnification.
remnants can cause diverse abnormalities, including congenital anomalies (patent urachus, umbilical-urachal sinus, vesicourachal diverticulum, urachal cyst) and acquired diseases (infection, neoplasia). Tumours are uncommon and may be benign (adenoma, fibroma, fibroadenoma, fibromyoma, hamartoma) or malignant (adenocarcinoma in 90% of cases, usually with intestinal-type histology) 44 . Urachal carcinoma accounts for 0.01% of all malignancies 27, 38 and 0.17%-1% of all bladder cancers 27, 38, 41, 44 .
Pseudomyxoma peritonei originating from mucinous neoplasm of the urachus is an extremely rare condition. We identified 18 previous cases in the English literature. Table i presents their distinctive features.
The collected cases present a variety of clinical pictures, stages at time of surgery, histologic types, and outcomes within a single clinical entity. The low number of reported cases and the differences in management and reported follow-up do not permit any generalizations or statistical assessments. However, we agree with the authors of earlier reports, that pmp originating from the urachus probably shares the pathophysiology, clinical behaviour, and prognosis of pmp with an appendiceal origin. Because peritoneal spread and local invasion dominate the clinical picture and present a major therapeutic problem, pmp originating in the urachus requires the treatment approach recommended for pmp arising from appendix rather than that for urachal adenocarcinoma 2, 34, 35, 41 .
Reported symptoms (Table i) are diverse, develop slowly, and usually remain unspecific: lower abdominal pain, distention, palpable mass, weight loss, intermittent bowel obstruction, hematuria, and urinary retention. Mucinuria because of persistent connection between the urachal remnant and the urinary bladder is highly distinctive for this disease 35 , but occurs relatively rarely. Physical examination (abdominal distention with so-called "jelly belly" ascites, and less often fever and peritoneal irritation) and laboratory tests (leukocytosis, anemia) are also not discriminative 33 . In an important proportion of cases (42%), elevated serum carcinoembryonic antigen and carbohydrate antigen 19-9 are present. Both markers are not disease-specific, but remain useful and recommended for primal diagnosis, evaluation of cytoreduction, and postoperative follow-up 28, 35, 45 .
Ultrasonography and computed tomography or magnetic resonance imaging, followed by histopathologic verification of extensively sampled tumour, are the preferred way to establish a diagnosis of pmp 37,46 . Ultrasonographic findings supporting a diagnosis of pmp of urachal origin are a large collection of intraperitoneal fluid and a midline-situated cystic tumour attached to the dome of the urinary bladder, often of heterogenous echogenicity, with multi-septation and intramural or septal calcification. Computed tomography and magnetic resonance images (especially T2-weighted sagittal images) of linear structure continuing from the tumour toward the umbilicus may complement other data.
Scalloping of the visceral surfaces and intestinal loop displacement evidence a large quantity of ascites and is discriminative with pmp 31,38,40 . Cytology examination of aspirated mucus has little diagnostic value, because acellular mucin often spreads further than do malignant cells 1 . Transurethral biopsies containing limited diagnostic material can provide false results because the tumour is often of heterogeneous architecture with focal invasive malignancy 47 .
The described lack of pathognomonic symptoms in combination with the slow and occult clinical course of this tumour usually results in disease being locally advanced at the time of diagnosis 34, 41 .
To the best of our knowledge, no generally accepted staging system has been applied in pmp. Among the 18 previously described cases of urachus-origin pmp (Table i) , most were at an advanced stage at clinical presentation. Six reports (including that of the present case) identified the presence of a solitary cystic tumour with various amounts of mucinous material containing sparse neoplastic cells, but without invasion into the urinary bladder. In 3 cases, the bladder wall was additionally infiltrated. A single synchronous extra-urachal locus of invasion was reported once. Multiple intra-abdominal tumour implants or peritoneal carcinomatosis was already present in 9 cases at the time of diagnosis.
In contrast to the natural history of urachal adenocarcinoma, pmp hardly ever gives rise to lymphatic and blood-borne distant metastases. However, it does show a strong tendency for local recurrence 2,33,41 . Consequently, the stage of local invasion throughout the peritoneal cavity is the first major prognostic factor 48 .
The second independent prognostic factor is the histologic grade of the causative malignant lesion 2, 7, 35, [41] [42] [43] 49 . According to data published by Ronnett and colleagues 7 , the 5-year survival rate in patients with pmp of appendical origin is 84% for patients with dpam, 37.6% for patients whose lesions have intermediate features, and only 6.7% for patients with pmca. Sugarbaker 43 = carbohydrate antigen 19-9; hipec = hyperthermic intraperitoneal chemotherapy; 5fu = 5-flourouracil.
The third main prognostic factor is completeness of cytoreduction 42, 43, 48 . Table ii presents the cc score published by Sugarbaker 43 . In pmp, the aim of surgical procedures is to excise all visible tumour, or if full excision is not achievable, to leave residual nodules less than 0.25 cm. The 0.25 cm diameter is considered the maximal achievable penetration distance for locally applied chemotherapy 41 .
Sugarbaker 43 describes 5-year survival rates of only 20% and no patient surviving 10 years after incomplete cytoreduction (cc-2 and cc-3). No significant differences in survival were observed for patients with cc-2 and cc-3 cytoreductions. Miner and colleagues 42 observed median survivals of 12.8 and 4.2 years after complete cytoreduction and incomplete cytoreduction respectively.
Abdominal distension, weight loss, invasion of major organs 1 , and (if prior surgery has been performed) a large extent of earlier surgical intervention 43 have also been assumed to be poor prognostic factors.
The optimal treatment for patients with pmp remains controversial. As mentioned earlier, peritoneal spread and local invasiveness are essential and defining for pmp, and surgical management (radical or partial cystectomy with en block resection of tumour, urachal remnant, umbilicus, and posterior rectus abdominus facia) might be insufficient for urachal adenocarcinoma 49 .
Most publications recommend, at least at the first operation, an aggressive approach resulting in complete cytoreduction (cc-0 or cc-1) with radical peritonectomy and resection of involved major organs, followed by perioperative intraperitoneal chemotherapy 2, 5, 27, [32] [33] [34] [35] 39, 41, 43 . That procedure has demonstrated prolonged survival at the cost of associated severe acute toxicity and elevated morbidity. Conversely, given that aggressive procedures reduce quality of life for patients and are usually not curative (high rates of recurrence are reported among longterm survivors), some authors prefer selective debulking. Miner and colleagues 42 suggest, that in case of advanced intra-abdominal spread, an aggressive surgical procedure does not ensure completeness of cytoreduction. In that group of patients, the authors advise a treatment strategy based on symptom management and preservation of function.
In the treatment protocol for pmp established by the Basingstoke and North Hampshire Foundation Trust Hospital (British National Tertiary Pseudomyxoma Referral and Treatment Centre), the cytoreductive procedure must include radical peritonectomy and removal of involved viscera to extirpate all visible tumour implants. Palliative debulking is performed if complete cytoreductive surgery is not achievable. Additional appendectomy and revision of ovaries to exclude the two main origins of pmp are advised 24 . Because radical cystectomy does not improve outcomes, a conservative partial cystectomy is usually recommended 2, 34, 37 . Thorough lavage of the abdominal cavity with mucolytic agents (5% dextrose in water or low molecular weight dextran solution) has been suggested to be beneficial 32 .
The surgical procedure must routinely be followed by perioperative intraperitoneal chemotherapy 2, 5, 27, [32] [33] [34] [35] 39, 41, 43 . Most recent studies suggest an essential advantage for application of hyperthermic intraperitoneal chemotherapy 24, 34, 35, 43, 48, 50, 51 . In cases of early-stage pmp with low malignant histology, some authors recommend not to dispense with intraperitoneal chemotherapy 39 . Only a few authors have described some benefit with systemic chemotherapy and radiotherapy. Nevertheless, such treatments can be applicable and useful for palliation in fast-deteriorating patients with recurrent high-grade malignant disease 2,3 .
SUMMARY
Although increasing numbers of cases of pmp have been reported, this neoplasm remains a diagnostic challenge because of its rarity and lack of discriminative symptoms. Pseudomyxoma peritonei should be considered in the differential diagnosis for abdominal and retroperitoneal tumours, especially with intercurrent ascites, because misdiagnosis delays effective treatment and affects survival.
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